Skip to content
‹ Back to IndustriesHealthcare

More Nations Pause Use of AstraZeneca Shot

The vaccination program in Europe has sunk further into disarray. The countries that are suspending the use of the AstraZeneca Plc. shot are rising. Germany, France, Italy and Portugal are just the latest countries to pause the use of the vaccine pending a further assessment by the European Medicines Agency. Bloomberg’s Maria Tadeo reports on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The vaccination program in Europe has sunk further into disarray. The countries that are suspending the use of the AstraZeneca Plc. shot are rising. Germany, France, Italy and Portugal are just the latest countries to pause the use of the vaccine pending a further assessment by the European Medicines Agency. Bloomberg’s Maria Tadeo reports on “Bloomberg Daybreak: Europe.”

“This is a PR nightmare for AstraZeneca. It’s a huge blow for that vaccine. And just the communications around it just really very much all over the place in Europe.” – Maria Tadeo

—

MANUS: What’s precipitated this caution, rising caution, by the heart of Europe? Good morning.

MARIA: Good morning Manus. Really it was that decision from Germany yesterday to suspend AstraZeneca. They worry about the blood clots. They say they want to figure out if this is a direct side effect from the AstraZeneca vaccine. And it’s the Germans taking that decision, very controversial decision yesterday, that really precipitated this domino effect from the French, from the Italians, from the Spanish. And if you move away from that, I guess you could say it’s legitimate to review a vaccine if there’s issues or concerns around it. The problem here really has been the communications, Manus. This has been all over the place for a week now. The European public very much whiplashed by a number of information that contradicts each other. And I would also say when you look at the statements still from the regulator the European Medicines Agency, still singing, still reiterating, ‘we still believe the benefits of the vaccine would outstrip the risks.’ So this is of course an issue about the vaccine. It’s about those concerns which may be, I want to stress, very legitimate on the blood clots. But really this is a PR nightmare for AstraZeneca. It’s a huge blow for that vaccine. And just the communications around it just really very much all over the place in Europe.

ANNMARIE: Right Maria. Some are suggesting this is a much a political decision as it is scientific. What happens next. I know there’s a number of meetings coming up this week.

MARIA: Yes Annmarie, and look, Emmanuel Macron yesterday said he was suspending the vaccine and he would do so until today and that he wanted to see further clarity from the European Medicines Agency. Now as I said just yesterday, the EMEA, the head of the European Medicines Agency vaccine unit, he was still repeating that he didn’t really see a problem with AstraZeneca. Nonetheless we know that there’s also a health ministers meeting happening today and that on Thursday there will be a review by the European Medicines Agency. Now at that point it could decide to pull that vaccine altogether or it could reiterate that message that it is still okay to use it for public health. But the question at that point, and this is really the question in Europe, is whether or not the damage here, the reputational damage on AstraZeneca, has been done already. We have seen many anecdotal evidence that when it comes to the take up, AstraZeneca is much more problematic than any other vaccine that’s on the market in Europe so far, Annmarie.

*Bloomberg contributed to this article.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512